Member Info for The_Paladin

@Nero8978

I doubt whether this is the actual "Movie 42" link. It appears to lead to a page from a previous version when the application was known as " Creator 42". I managed to sign in, and the link led to a project development application called "lovable". This appears to be interesting and useful in itself, but there is no obvious indication that it is an R42 project?

https://lovable.dev

With regard to the expected RNS, I view it as being mostly of interest to shorter term traders, as opposed to "spiked" long term investors like myself. For what it is worth, I now need around a 2.2p share price to turn a small profit on this stock. Decisions will need to be taken should it rise above that level? I am most likely to hold for the long term though. Selling stocks in anticipation of a price drop, in order to buy in lower, requires a level of expertise that I don't have. Should the Author 42 ecosystem turn out to be successful in time, longer term investors should eventually reap a better return than that obtained by today's short term traders. All this remains to be seen? Meanwhile, Author 42 is launched, and retail investors like myself will look forward to subsequent developments.

GLA

@Crownos

@Wessy1

@Goodlife

I had similar experiences to Crownos and Wessy1 when attempting to access Author 42. It didn’t recognise my login details, and the promised confirmatory e mail did not arrive. I attempted the login on several devices before finally succeeding by logging in with my google identity.

There is apparently a ‘bug’ in the fiction component as attempting to access it led me to a different platform, which doesn’t seem to be related to Author 42?

I believe that Goodlife’s e-mail, which I have also just received was sent to potential subscribers, who had requested to be informed once the Author 42 platform was officially launched.

My short attempts with Movie 42 and Game 42 gave identical results as those obtained by others. Both of these are early stage, with apparently a lot of work still needed.

The bottom line be is that a product has been launched, with further information to follow next week.

I was disappointed with the trading fiasco yesterday. The stale warrants suggestion is the best explanation for this? The initial launch of CapAI misled investors for several reasons, including the legacy warrants. This issue will eventually disappear altogether, and Prof Nag will finally be able to go ahead with introducing selected products into the CapAI ecosystem without further hindrance.

The subsequent marketing, and commercialisation will take time. Traders will come and depart along the way. I am hoping that LTIs like myself, who have remained on board will eventually accrue a good increase to our investment.

GLA.

As we wait for the hard launch of Author 42, and for Game 42 and Movie 42 to go live, later this week, I turned my attention to CapMedical.

Yesterday’s announcement suggested that potential CapMedical products are being carefully assessed by Prof Nag’s small teams prior to the allocation of funds for further development.

His numerous R42-based messages on LinkedIn gives some idea about the areas being explored. In addition, I found the following article from late 2024, which gave me further detailed insights on the direction that CapMedical might move in?

https://www.brventurefund.com/4808-2

In my view, we are still early stage, and I shall be taking matters one step at a time, starting with the forthcoming CapMedia developments.

The potential is enormous, but I have thought the same about other companies, which did not succeed. This feels different, mostly due to Prof Nag’s energy and drive. Time will tell, and I intend to remain invested for the long haul. I shall review my position should the share price reach 10p? I don’t anticipate reaching that level anytime soon.

GLA.

I view today’s announcement as the much awaited firing of the starting pistol to a long race. CapAI’s “X”message sums it up reasonably well.

“ Update: capAI plc (LSE: CPAI; OTCQB: CPIQF) moves into live deployment with multiple AI platforms launching ahead of today’s AGM, marking a shift to commercial validation. Continued focus on disciplined growth and AI-enabled longevity opportunities.”

Unfortunately today is all about traders and their short term gains. I am invested for the long term, and am now more assured about topping up my ISA on April 8.

As anticipated, the initial commercial launch is all about CapMedia products within an integrated ecosystem. There are years of continuous development of these products ahead, and hopefully they will bring in significant revenues ?

I don’t have much idea about CapMedical, although Prof Nag’s R42 based LinkedIn messages give us some idea about what might lie ahead?

I am also hoping for an improvement in the quality of this forum. There have been too many green rectangles on my screen of late. I wish that those who abuse others, and have no real interest in this company, would take themselves to a suitable low level thread on a social media platform, more appropriate to their perverse needs.

GLA.

Very recently we have been informed about Prof Nag’s interest in R42 fellowships, improving sleep, and Vitalist 2026. In his latest comment, he turns his attention to yoga. It would be good to learn in next Tuesday’s AGM whether any of his prolific ventures are actually linked to CapAI? A significant Author 42 update would be more than welcome - anything to kick start this company from its stagnation. GLA.

“Yoga is great for longevity. Breathing, meditation and stress reduction”. …. Prof Nag.

https://luma.com/n5erkdkz

Prof Nag is one of the 40 speakers at this conference which will be held between 24 and 27 May. His comment on this: “Always a lot of fun, and learn something new”.

Where does the time for CapAI fit into his crowded agenda? I wish that I was able to attend next Tuesday’s AGM to raise that very issue.

I hope that I am proved wrong in my “judgement” on Prof Nag’s very busy schedule, and that we receive a significant update concerning Author 42 next week.

All I can discover for the time being is updates to websites, and LinkedIn profiles.

Investors need more concrete information for reassurance. What we were led to believe would happen has not materialised within the expected timeline.

“Announcing: 40 new speakers for @VitalistBay 2026! 100+ total.

The lineup includes 𝗠𝗼𝗿𝗴𝗮𝗻 𝗟𝗲𝘃𝗶𝗻𝗲 (Altos Labs, built the epigenetic clocks that redefined biological age), 𝗘𝗿𝗶𝗰 𝗩𝗲𝗿𝗱𝗶𝗻 (CEO of the Buck Institute, 210+ papers, top 1% most cited in aging), 𝗚𝗿𝗲𝗴 𝗙𝗮𝗵𝘆 (ran the first clinical trial to reverse human epigenetic aging), 𝗧𝗶𝗺 𝗖𝗵𝗮𝗻𝗴 (Mayfield Fund, 2x Forbes Midas List, $2.6B+ in exits).

May 14–17 · Berkeley, CA · 6 tracks · 40+ wellness activations · onsite health testing

🎟 Tickets: vitalistbay.com First 5 to use code LI-SPEAKERS99 → $99 tickets ($850 OFF!)

Which speaker are you most excited to see?

#VitalistBay #Longevity #Biotech #AgingResearch”

I have just forwarded the following message to CapAI via their e-mail address. Let us see if they respond quicker this time. It took several months for R. Edwards’ profile to be removed, and J Allardyce’s profile to be added, following my last e-mail.

My e-mail:

Please note that Sarah Davy’s profile needs to be updated. It doesn’t make sense as it stands.

(There is no link to “Richard” in the CapAI team profiles)

“Sarah is a highly experienced accounting and tax professional with a strong background in strategy and significant experience in dealing with complex, high-value and international transactions. Sarah works alongside Richard as a Partner at a boutique firm of Chartered Accountants.”

The only update from Prof Nag this morning is about how to improve our sleep. It is another R42 initiative, with no apparent link to CapMedical?

CapAI’s AGM will be held next Tuesday. The agenda is straightforward, and it doesn’t look as if there is an Author 42 update scheduled? I note that two of the U.K. directors have put themselves forward for reelection. I am not aware that they have contributed anything during the last year? One of them needs to update her profile on CapAI’s website. It doesn’t make sense as it stands.

The following link provides another link to a PDF file with the AGM agenda:

https://www.capai.group/investors

GLA

“This will be a great course to improve sleep, which helps in recovery, immunity and cognition all at once !”

…… Prof R. Nag.

Below is the R42 LinkedIn message to which Prof Nag is referring:

“You're probably sleeping worse than you think.

Most people don't track Sleep. They track steps, calories, workouts, everything else.

Sleep gets whatever's left over.

But here's what the research shows: sleep determines your cognitive performance, metabolic health, and biological aging. Centenarians across all Blue Zones share one non-negotiable: consistent, quality sleep.

This April, we're hosting a 4-week course with Dr. Martin Kawalski from Stanford University. He investigates how consumer wearables can quantify the impact of disrupted sleep on aging.

You'll learn:

• Sleep architecture and how it changes with age

• Which wearable metrics actually matter (and which ones are noise)

• Why centenarians maintain less than 15-minute bedtime variation

• Evidence-based interventions ranked by impact

• How to build a 90-day sleep optimization plan

Sleep is the most underutilized longevity lever.

Time to use it.

Starting April 21. Register: https://luma.com/ov35356l “

Despite the lack of formal notification, there have been some developments in the background, in that both the Author 42 website, and the CapAI website have been brought up to date. The latter makes the link between R42 and CapAI more explicit, and fully explains the company's rationale. At last, we also have an updated list of the company's directors. The fiction authorship tools are not there yet, but I get the distinct impression that they may be forthcoming?

Nothing to get excited about, but some encouragement nevertheless.

https://author42.com

https://capai.group

GLA

I also topped up my ISA holding on April 8. I didn’t sell the CapAI shareholding in my trading account, however. Hopefully that may eventually turn a profit despite being well down for the time being?

I wrote to Jayne Lytel a few weeks ago to offer encouragement. I did not expect a reply, but she responded within hours. She stated that it wasn’t part of her role to communicate with investors, but encouraged me to write to Prof Nag if I had any questions concerning strategy and deadlines.

JL’s revised job description on LinkedIn offers clues as to how CapMedia may evolve over time?

“ 𝐀𝐫𝐜𝐡𝐢𝐭𝐞𝐜𝐭𝐢𝐧𝐠 𝐭𝐡𝐞 𝐍𝐚𝐫𝐫𝐚𝐭𝐢𝐯𝐞 𝐄𝐜𝐨𝐧𝐨𝐦𝐲: Leading the design of Author42, Creator42, and Game42, creating a unified ecosystem for cross-platform storytelling.

𝐀𝐮𝐭𝐡𝐨𝐫𝐢𝐚𝐥 𝐒𝐨𝐯𝐞𝐫𝐞𝐢𝐠𝐧𝐭𝐲: Engineered CLARA42 (Creative Literary Assistant for Real Authors), an AI manuscript editor that utilizes neural frameworks to provide developmental and line editing while strictly preserving the author's unique voice.

𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐭𝐞𝐥𝐥𝐢𝐠𝐞𝐧𝐜𝐞: Developed Trendspotter42, a tool that leverages generative AI to help authors analyze publishing trends and optimize market positioning.

𝐕𝐢𝐛𝐞 𝐂𝐨𝐝𝐢𝐧𝐠 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Pioneered the use of vibe coding to build immersive, interactive applications that lower the barrier for creators to engage with AI-assisted writing.”

Her website may indicate the type of context that may be realisable using Author 42?

https://jaynelytel.com/

Some intriguing prospects, but investors will have to remain patient until the next CapAI update.

GLA

Prof Nag regularly promotes his various R42 small companies, and projects. It is unclear how these will relate to CapAI? We haven’t received any communication since the vague strategy update on Feb 10. Prof Nag’s online presentation to attract investment was of a similar quality.

The only indication of what is going on with Author 42 is in the change in Jayne Lytel’s job description on LinkedIn. I am inclined to believe that developments in CapMedia might well align with her personal online authorship style- a combination of words, images, video and songs? There is no indication that JL is using Author 42 (which remains under development) to generate her content.

Incidentally, Claire Lu has changed her Linked in profile, with the vaguest of reference to Author 42.

Prof Nag’s latest Linked In message:

“R42 Fellows program is now open. FREE. Starts June 15. Minimum age 18. 10 weeks online. Learn AI, and be placed on a cutting edge AI project. The projects are below and apply here: https://lnkd.in/g7WX8Wvx

Stockmarket Prediction: predict the stockmarket with AI.

R42 Ageotype Project: Provide health recommendations from AI

R42 Agentic AI Platform: build and run an entire company with an “AI Army.”

BioNeural AI Computing: Interface biological neurons with semiconductors.

Media AI Content Creation Platform Using generative AI, agentic workflows, to develop narratives, characters, and worlds.

R42 Podcast: Create the R42 Podcast is a media platform focused on at the intersection of artificial intelligence, longevity science, and venture capital, and entrepreneurship.

​

AI Growth Hacking Platform: guide users from audience discovery through content creation, relationship building, and offer conversion

Superbio.ai AI Scientist Agent: make an AI scientist agent.”

GLA.

Investors are still waiting for an update from Prof Nag and, in the first instance, the Author 42 small team.

Until this arrives, all comments and speculation on this forum and elsewhere are largely irrelevant.

We simply cannot write off this company nor predict its future success until we receive that crucial update - hopefully sometime during Q2.

GLA.

The question that remains, one year later, is when Prof Nag intends to deliver on his promises?

For too long, this company has only delivered a daily dose of misery to its longer term investors.

A major question is whether this company should have been set up in the first place? More than one year later, there isn’t a single product ready to be marketed. There are no visible income streams. The fact that the former executive chairman, under whose direction a x10 dilution was introduced to no good effect, ditched the company shortly afterwards raises questions. The aforementioned former chairman also took the he company to the US market, apparently to no good effect?

I am beginning to question whether this company was ever a viable investment. Prof Nag is an excellent communicator, but his attention seems to be constantly directed elsewhere? Similarly, the two named individuals developing and marketing Author 42 regularly comment on their other interests?

I am certain that I am not alone in questioning why I ever invested in this company? Thus far it has been a case of all talk and zero delivery.

GLA.

Check it out (below). There has been no discernible progress with the Author 42 app during Q1. As far as I can tell, its status is the same as wad the case last December. The mobile app, and greater flexibility in enabling fiction as well as non fiction to be authored still haven’t emerged.

The strategic update, early last month, was wordy and in places repetitive without going into any detail or timelines. A bit like Prof Nag’s recent online presentation for potential investors. All promise and no delivery.

When Prof Nag joined CapAI, it was heralded as a golden moment for the company. I am still keeping faith with him, despite being disappointed with the lack of progress during the last year, and the endlessly declining share price.

I have decided to “bottom drawer” my holding and hope for the best. I shan’t be investing any more of my hard earned money in this company - at least not until Prof Nag starts to launch several products for development in CapAI, with a positive response from the market. For the moment it feels as though investors have been badly let down by everyone associated with this company.

GLA.

https://author42.com/mobile-coming-soon

There was a similar message (below), on LinkedIn, and concerning supplements, earlier today from Claire Lu. Claire is employed as Author 42’s Growth Hacker.

I doubt whether any of this is connected to CapAI?

The Feb 10 RNS offered an extensive strategic update , mostly an outline which lacked any detail. By now it seems that Author 42 and the other associated CapMedia developments are not progressing as quickly as investors had hoped?

Surely Prof Nag is not monitoring CapAI’s share price? Unless he issues a prompt detailed positive update, the share price will sadly continue on its catastrophic decline.

To view Claire Lu’s LinkedIn comment, you will probably first need to Login on the LinkedIn app beforehand accessing the link below.

https://www.linkedin.com/posts/yanbing-lu_yes-im-in-my-20s-and-ive-already-started-share-7440923991646650368-tE27?utm_source=share&utm_medium=member_ios&rcm=ACoAAFkZSG4BdxpM6GmnCyXnIP2qbL5EnrbABqc

GLA.

I haven’t checked this board since last Thursday. The fact that I have seven consecutive green rectangles on my screen since then is most likely a reflection of the quality of communication?

The lack of communication from the company throughout Q1 is concerning. Sensible investors are announcing that they are moving elsewhere.

The previous chairman offered regular updates, most of which were structural, and did nothing to visibly improve the investment case.

Prof Nag’s multiple preoccupations, and involvement with other micro-companies throughout Q1 implies that his interest in CapAI is at best minimal? His recent presentation to potential investors did little to inspire confidence.

It is time that the vision that was offered at the company’s launch were realised. To date, the only beneficiaries since CapAI’s launch are the short term traders, and warrant holders.

GLA.

Another vague message from Prof Nag, posted on a discussion forum, is highly unlikely to add a positive spark to the current situation.

Most shareholders, including myself, made a serious error in investing in this venture way too soon. Sadly, Prof Nag’s involvement has been minimal to date. His reputation as an innovative developer of technical products is the only reason that most of us decided to back this company. The other board members are at best an irrelevance, and there has been zero interest from them since Richard Edwards’ departure three months ago. It is also fair to day that there has been no discernible progress since then.

At the very least, the company needs to issue a SUBSTANTIAL statement regarding its progress from Prof Nag. I agree with others that his recent presentation to investors added nothing. Unfortunately he wasn’t sufficiently prepared to deliver his statement with the conviction needed to persuade new investors to come on board. Since then, there has only been persistent selling with accompanying share price decline.

I do not want to add to the unfortunate negativity on this forum, other than to say that I am disappointed by the lack of progress to date with Author 42. A single positive RNS on that subject could instantly reverse the constant day by day selling of CapAI stock.

In case the gloating uninvested (possibly warrant sellers), who have occasionally “popped up” here, choose to respond with their pointless comments, as before, I would urge them not to bother. I have filtered their unhelpful drivel together with that of others, who only contribute incoherent negativity to this forum.

Good fortune to all CapAI investors.

Good wishes to all CapAI investors.

My monthly check on the status of Author 42 showed nothing new. Perhaps Prof Nag should have delayed his recent online investor “update” until there was something to report? He seems to be preoccupied with his R42 initiative on teaching vibe coding, and with many other diverse projects at the present time.

Here is the current, AI-generated, status of Author 42:

Author42, developed by capAI plc (often referred to in the context of R42 or capMedia), is in the soft launch phase as of November 2025, which is the final stage before full commercial release.

Soft Launch Phase (Nov 2025): The platform is currently being released to a controlled early-access cohort to validate onboarding, refine workflows, and test pricing/support before a general rollout.

Previous Testing: The soft launch followed a 12-week public beta programme that evaluated the platform's stability and core systems.

Availability: It is offered via a tiered subscription structure, starting with a free plan and paid plans beginning at US$20 per month.

Feature Expansion: While the core platform is in soft launch, specialized components for fiction authors, including "VOICE42" (Voice Optimization & Idiolect Calibration Engine), are expected to become available in early 2026.

Key Capabilities:

Author42 is designed as a generative-AI platform for non-fiction book creation, offering features like AI-scaffolding, professional editorial workflows, and market-driven insights to speed up the writing process.

I am hoping that CapAI will have its commercialisation strategy underway sometime during H1?

GLA.

The above header isn’t a bad way of describing CapAI on all fronts.

When the company was launched, the concept made a lot of sense, especially with Prof Nag on board. Investors, including myself, didn’t understand the time scale involved, hence the unacceptable decline to our shareholdings that we have all experienced, apart from more savvy recent investors, that is.

Some time ago, I wrote to CapAI concerning the misinformation on the Companies House statements. They have since been corrected, although the CapMedical and CapMedia documents still don’t include Prof Nag. As he is the only director with any real influence, it seems unreasonable not to include him.

Our website still includes Richard Edwards as a director (no Jack Allardyce). The same may be said about the information listed by the company which hosted Prof Nag for his recent presentation. Personally, I find this unacceptable, especially as I have sent CapAI two e-mails about this (without receiving a reply).

It is obvious that our directors are doing little, if anything at all, at present, while awaiting the launch of Author 42. Their combined inaction has resulted in the decline in investor interest reducing our share price to its present level.

This offers an excellent opportunity for new investors, provided CapAI comes good that is?

I previously believed that Author 42 would have been launched well before now, and await any developments with interest.

A year ago, Richard Edwards and his associates launched a company. As it turned out, he launched an “Emperor’s New Clothes” scenario. CapAI remains totally “in the altogether” for the time being. I hope that Prof Nag will soon take the necessary action to turn the current long lasting decline around with the promotion of a few innovative AI based micro companies, both in the media and medical scenarios.

GLA.

Unfortunately, Prof Nag appears to have very many irons in the fire. He appears to be a in a constant state of flux, and speaks on diverse subjects at a number of conferences and symposia, as well as maintaining multiple other roles.

In theory, this shouldn’t affect CapAI too much provided there are projects under its umbrella that are attracting interest, and generating revenue streams.

The process hasn’t yet properly started. Our first authorship software will hopefully be ready for release during H1 - this year.

Until that happens, our share price is still in the grip of sellers. I have recently read Richard Edwards’ CV, and some of his comments on X regarding his investments. It baffles me how his funding strategy for CapAI has resulted in our current situation, which is still ongoing day by day.

Surely, Mr Edwards didn’t visualise this happening when he made the funding arrangements a year ago?

The company was launched way too soon. There should have been at least one product ready to launch a year ago? Hindsight now suggests this, and investors, like myself misjudged the time scale needed to get the venture properly underway?

I read with interest that a number of investors are pinning their hopes on successful products in the CapMedical sphere? I shall be interested to see how the CapMedia side plays out with the launch of linked multi-media products perhaps? Jayne Lytel’s online output is interesting, and may give an idea as to how the multi media products might work together?

Prof Nag’s recent presentation fully explained the concepts underpinning my investment. Unfortunately it apparently hasn’t attracted any further interest? Our current situation may well change if the various facets of CapAI’s strategy work well together in generating interest and with it revenue? As previously stated, we will know how the land lies once Author42 v1 is finalised and launched.

GLA.